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Abstract 
Purpose: To investigate if cordycepin (Cor) exerts synergistic anticancer and antibacterial activities with 
curcumin (Cur), resveratrol (Res), genistein (Gen), and anthocyanidin (Ant) in order to improve its 
therapeutic effect.  
Methods: Antibacterial activity was assayed against Escherichia coli BL21 (DE3) cultured in the Luria-
Bertani (LB) medium, while anticancer activity against Hela cells was determined using 3-(4, 5-
dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT) assay. Immunofluorescence assay was 
used to measure the expressions of p53 and caspase-3, while apoptosis was assayed in Hela cells 
using Wright-Giemsa dye staining method. 
Results: The combination of Cor and Gen produced the most significant synergistic antibacterial 
activity, while combination of Cor, Cur and Gen exerted significant and synergistic anticancer activity 
against Hela cells. Among all three-compound combinations, Cor + Res + Gen had the highest 
synergistic anticancer activity. Immunofluorescence data indicate that Cor functioned by up-regulating 
p53-dependent apoptosis, while Res exerted its effect by p53- and caspase-3-dependent apoptosis, 
and Gen functioned by inhibiting adenosine deaminase and Cor degradation.  
Conclusion: The three compounds function via different mechanisms, and synergistically induce Hela 
cell apoptosis. This work provides a strong basis for the development of highly active and multi-
component anticancer drugs from natural sources.  
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INTRODUCTION 
 
Natural bioactive compounds have been shown 
to exhibit various therapeutic effects, such as 
anticancer [1,2], antibacterial [3], antioxidant [4] 
and anti-diabetic properties [5]. Bioactive 
compounds derived from natural sources show 
diversity in terms of chemical structures, 
biological activities and mechanisms of action. 
However, most natural compounds have 
disadvantages such as relatively low efficacy, 
delayed activity at the site of action and/or fast 
degradation which restricts their potential 
applications as clinical drugs [6].  
 
-----------------------------------------------------------------------------------------------------------------------------------------------------
© 2018  The authors. This work is licensed under the Creative Commons Attribution 4.0 International License 
 
 
Ni et al 
Trop J Pharm Res, August 2018; 17(8): 1622 
 
Numerous reports indicate that bioactive 
compounds with varying chemical structures may 
act at different drug targets through multiple 
mechanisms or signaling pathways for the same 
disease. They may synergistically function as 
multi-target drugs at low doses [7]. Synergistic 
interactions are common between anticancer 
polyphenols, and also between anticancer 
chemotherapeutic drugs and phenolic 
compounds [8]. It has been demonstrated that 
the combination of Cur (20 µmol/L) and Gen (100 
µmol/L) effectively inhibited angiogenesis in 
human prostate cancer cells, as indicated by 
significant decline in the expressions of ARNT 
and HIF-1α protein [9].  
 
Apigenin and Cur produce synergistic anticancer 
activity by binding at different sites of tubulin [10]. 
The combination of Cur and ellagic acid at 
various concentrations elicited better anticancer 
properties than when used singly [11]. It has 
been reported that cucurbitacin-induced 
apoptosis in human hepatoma cells was 
synergistically enhanced by Cur, which also 
reversed cucurbitacin-induced multidrug 
resistance in these cells [12]. Combination of 
Res and thymoquinone synergistically reduced 
tumor growth in breast cancer mice by induction 
of apoptosis, inhibition of angiogenesis, and 
immune modulation [13]. 
Cordycepin (Cor) is an important bioactive 
compound isolated from Cordyceps militaris. It 
has anticancer, antibacterial, and immune-
regulatory properties [14]. However, many 
studies have shown that the effectiveness of Cor 
in vivo is limited due to its rapid deamination by 
adenosine deaminase [15,16]. Preliminary 
studies have identified a number of phenolic 
compounds which inhibit the activity of 
adenosine deaminase [17]. In the present study, 
the antibacterial and anticancer activities of Cor 
in combination with several bioactive phenolic 
compounds, were investigated. 
 
EXPERIMENTAL 
 
Preparation of natural products 
 
Cordycepin (Cor) was prepared as described 
previously [14]. Curcumin (Cur), Res, Gen, and 
Ant were purchased from Qiyun Biotechnology 
Ltd, China. Antibodies for p53 and caspase-3, 
and Goat anti-Rabbit IgG/FITC were purchased 
from Boster Biological Technology Co. Ltd, 
China. These compounds were more than 98 % 
pure, and were dissolved in water or 4 % (v/v) 
ethanol prior to use. This research was approved 
by the Ethical Committee of Guangdong 
Provincial Key Lab of Biotechnology for Plant 
Development, School of Life Sciences, South 
China Normal University, Guangzhou 510631, 
China according to the declaration of Helsinki 
promulgated in 1964 as amended in 1996, the 
approval number is 2804 [18]. 
 
Antibacterial assay 
 
Escherichia coli BL21 (DE3) was cultured in the 
Luria-Bertani (LB) medium for 3 h at 37 ℃. Then, 
different concentrations of Cor, Cur, Res, Gen, 
and Ant were added to the inoculum and cultured 
for another 6 h. The absorbance of the culture 
medium suspension (as a measure of bacterial 
growth) was read at 600 nm in a 
spectrophotometer (model 6105, Jenway, Essex, 
UK). 
 
Evaluation of anticancer activity  
 
The anticancer activities of Cor, Cur, Res, Gen, 
and Ant were determined using standard 3-(4, 5-
dimethylthiazol-2-yl)-2, 5- diphenyltetrazolium 
bromide (MTT) assay. Hela cells were grown in 
96-well plates at the concentration of 20,000 
cells/well in 200 µL (Roswell Park Memorial 
Institute (RPMI 1640) medium. The cells were 
allowed to attach overnight, after which various 
concentrations of Cor, Cur, Res, Gen, and Ant 
were added to separate wells. At 24, 48, and 72 
h of incubation, 20 µL of 0.5 mg/ml MTT reagent 
(Sigma-Aldrich Co. Ltd., Poole, UK) was added 
to each well. After 4 h incubation, the culture 
solutions were removed, and 500 µL of dimethyl 
sulfoxide (DMSO) solution was added to each 
well to solubilize the formazan crystals formed. 
The absorbance of each well was read at 530 nm 
in an Ultra Multifunctional Microplate Reader 680 
(Bio-Rad, Hercules, CA, USA). The experiment 
was repeated three times. 
 
Determination of apoptosis  
 
Apoptosis was assayed in Hela cells stained with 
Wright-Giemsa dye solution. After treatment with 
Cor, Cur, Res, Gen, and Ant for 48 h, the cells 
were stained with Wright-Giemsa dye solution 
according to the manufacturer’s instructions, and 
examined using light microscopy [19,20]. 
 
Determination of p53 and caspase-3 
expressions by immunofluorescence  
 
Following treatment with Cor, Cur, Res, Gen, and 
Ant, Hela cells were rinsed twice in phosphate 
buffered saline (PBS), fixed in 100 µL 4 % 
paraformaldehyde for 30 min, rehydrated in PBS, 
and incubated with the primary antibodies 
overnight at 4 ℃. Thereafter, the cells were 
rinsed with PBS and incubated with anti-rabbit 
IgG, followed by streptavidin-conjugated FITC (1: 
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200 dilution in blocking solution) for 2 h [21,22]. 
After washing with PBS, p53 and caspase-3 
expressions were assessed under inverted 
fluorescence microscopy (Eclipse TE2000-U, 
Nikon Tokyo, Japan). 
 
Statistical analysis 
 
The results are expressed as mean ± standard 
deviation (SD) of at least three replicates. 
Statistical analysis of the data was performed 
using SPSS software, version 22 (IBM). Data 
were analyzed by analysis of variance (ANOVA) 
and significant differences (p < 0.05) were 
detected by Scheffé’s post hoc test. 
 
RESULTS 
 
Antibacterial activity of individual 
compounds 
 
As shown in Figure 1, Gen had the highest 
antibacterial activity; it inhibited microbial growth 
by 60 % at 200 µmol/L. A similar inhibition 
efficacy was produced by Cur (57 %) at 100 
µmol/L, but its activity did not increase further 
when the concentration increased to 200 µmol/L. 
Moderate and concentration-dependent 
inhibitions were exhibited by Cor and Ant against 
the growth of E. coli. The only compound that did 
not produce dose-dependent antibacterial effect 
was Res. It inhibited bacterial growth by 37 % at 
a dose of 50 µmol/L, but its inhibitory effect 
decreased at higher concentrations (100 and 200 
µmol/L). The antibacterial activities of the five 
compounds tested followed the order Gen > Cur 
> Cor > Ant > Res. 
 
 
Figure 1: Inhibition of E. coli growth by Cor and 
phenolic compounds at different concentrations 
 
Cor produced synergistic antibacterial 
activity with phenolic compounds  
 
The results shown in Figure 2 demonstrate that 
Cor produced relatively low antibacterial activity. 
In order to improve its activity, it was used in 
combination with other tested compounds to see 
if the combinations would produce synergistic 
antibacterial activities. The combination of Cor 
and Gen at 50 µmol/L produced significant 
synergistic antibacterial activity, reflected in 60 % 
inhibition of microbial growth (p < 0.05). This was 
450 and 77 % higher than the activity shown 
individually by Cor and Gen, respectively. Other 
compounds such as Res, Cur and Ant did not 
show any synergistic antibacterial activity and the 
activities of their combinations with Cor were 
even lower than values obtained when they were 
tested individually. 
 
 
Figure 2: Inhibition of E. coli growth by Cor in 
combination with phenolic compounds at 50 µmol/L 
 
Anticancer activity of Cor and phenolic 
compounds  
 
The anticancer activities of individual compounds 
(Cor, Res, Cur, Gen, and Ant) against Hela cells 
were determined at concentrations of 5, 25, 50, 
100, and 200 µmol/L. As shown in Figure 3, all 
the compounds significantly inhibited Hela cell in 
a dose- and time-dependent manner. The 
highest anticancer activity was produced by Cur, 
with approximately 90 % growth inhibition in 72 
h, at concentrations higher than 100 µmol/L. The 
inhibitions produced by the other compounds 
followed the order Res > Ant > Cor > Gen. 
 
Cor showed synergistic anticancer activity 
with phenolic compounds 
 
Significant synergistic inhibition of the growth of 
Hela cells was produced by a combination of 
Cor, Cur and Gen at 50 µmol/L, when compared 
with the inhibitions produced by single 
compounds (Figure 4). The inhibition by 
combination of Cor and Cur increased more than 
75 % and 17 %, relative to single Cor and Cur 
treatments, respectively. The inhibitory effect by 
Cor + Gen mixture increased by more than 50 %, 
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when compared to individual Cor or Cur 
treatments at the same dose (50 µmol/L). 
However, the combination of Cor with Res or Ant 
failed to produce any synergistic inhibitory effects 
on the growth of Hela cells. 
 
 
Figure 3: Inhibition on Hela cells at 5 ( ), 25 ( ), 
50( ), 100 ( ), and 200( ) µmol/L for 24, 48, and 72 
h by Cor and phenolic compounds 
 
 
Figure 4: Synergistic inhibition on the growth of Hela 
cells at 50 µmol/L by Cor in combination with phenolic 
compounds 
 
The synergistic anticancer activities of Cor with 
two phenolic compounds were also investigated 
at a reduced dosage of 25 µmol/L. The results in 
Figure 5A showed that all five three-compound 
combinations yielded synergistic anticancer 
activities, which were significantly higher than 
those produced by their components when used 
singly. The three-component combination of Cor, 
Res and Gen (25 µmol/L) had the highest 
anticancer activity, which was considerably 
higher than that produced by Cor, Res or Gen 
when tested alone. A similar pattern of results 
was obtained with respect to the effects of the 
treatments on apoptosis (Figure 5B). When 
compared to the control and treatments with 
individual compounds, Hela cell volume and 
number were significantly decreased in the 
combined treatment with Cor, Res and Gen. Hela 
cells showed nuclear condensation and early 
apoptosis after 48-h treatment, which indicated 
that the combined treatment with Cor, Res and 
Gen exerted significant synergistic anticancer 
activities (p<0.05). 
 
 
Figure 5: Synergistic inhibition of Hela cells by Cor in 
combination with two phenolic compounds at 25 
µmol/L 
 
Caspase-3 and p53 expressions  
 
The expression of p53 and Caspase-3 were 
studied in the combined treatment of three 
compounds (Cor + Res + Gen) with 
immunofluorescence analysis to investigate the 
mechanism involved in their anticancer activities. 
As shown in Figure 6, Cor and Res up-regulated 
p53 expressions, whereas Gen did not produce a 
similar effect. The combination of Cor, Res and 
Gen synergistically produced higher level of up-
regulation in p53 expression. As shown in Figure 
7, Cor and Gen did not induce caspase-3 
expression, while Res up-regulated it. However, 
the combination of Cor, Res and Gen exerted a 
synergistic effect by up-regulating caspase-3 
expression and inducing Hela cell apoptosis. 
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Figure 6: Immunofluorescence analysis of p53 
expression after treatment for 48 h  
 
 
Figure 7: Immunofluorescence analysis of caspase-3 
expression after treatment with different natural 
products for 48 h 
 
DISCUSSION 
 
Although Res inhibited bacterial growth by 37 % 
at a dose of 50 µmol/L, its inhibitory effect 
decreased at higher concentrations. Indeed, Res 
was the only compound that failed to produce 
dose-dependent antibacterial activity. Low 
inhibitory activity of Res against gram-positive 
bacteria has been previously reported [23]. 
 
The only significant synergistic antibacterial 
effect was produced by combination of Cor and 
Gen at 50 µmol/L, which resulted in much higher 
antibacterial effect than when the compounds 
were used singly. It has been previously reported 
that Cor is an NAD+-dependent DNA ligase 
inhibitor which inhibits bacterial growth [24], 
whereas Gen inhibits DNA and protein synthesis 
in Klebsiella pneumonia [25]. Therefore, Cor and 
Gen may mediate their antibacterial activities 
through different mechanisms, which manifested 
in a synergistic inhibitory effect on E.coli growth. 
Furthermore, Gen is known to inhibit the activity 
of adenosine deaminase [17]. Thus, it may 
function by inhibiting the degradation of Cor in 
cells.  
 
The results of combination of Cor, Res and Gen 
suggest that Cor and Res can induce p53 
expression and activate the p53-dependent 
apoptotic pathway. Res could also up-regulate 
caspase-3 and activate the caspase-3 dependent 
apoptotic pathway. On the other hand, Gen did 
not show any activity on both p53- and caspase-
3-dependent pathways. Since Gen is able to 
inhibit adenosine deaminase activity, it may 
function by inhibiting the degradation of Cor 
[17,31]. All three natural compounds may have 
acted on both p53- and caspase-3-dependent 
apoptotic pathways, thereby inhibiting the growth 
of Hela cells in a synergistic fashion.  
 
A large body of evidence indicates that Cor 
exerts significant in vitro anticancer activity 
against different cancer cell lines [26,27]. 
However, the therapeutic effect of Cor on human 
cancer cells is not ideal due to its fast in vivo 
degradation by adenosine deaminase. In order to 
improve its inhibitory effect and reduce dosage, 
synergistic anticancer activities of Cor with the 
phenolic compounds were investigated.  
 
As a regulator of the apoptotic process, p53 
modulates key control points in both the extrinsic 
and intrinsic pathways. Up-regulation of p53 
expression in tumor cells can induce apoptosis 
[28,29]. In mammals, caspases appear to be 
activated in a protease cascade that leads to 
inappropriate activation or rapid disablement of 
key structural proteins such as important 
enzymes involved in signaling, homeostasis and 
repair. Caspase-3 is a frequently activated death 
protease. It is a key protease in apoptosis, and 
an important target in cancer therapy [30]. 
 
CONCLUSION 
 
The results obtained in this study show that the 
combination of Cor and Gen exerts synergistic 
antibacterial activities, while the combination of 
Cor, Res and Gen produces significant 
synergistic anticancer activities through different 
apoptosis-related pathways. These findings 
demonstrate that different natural bioactive 
compounds can be combined to act as a multi-
component drugs which synergistically inhibit 
bacterial and cancer cell growth at relatively low 
concentrations. These results provide useful 
clues for the development of new drugs with 
potential anticancer activities from natural 
compounds. 
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